Analysts’ Opinions Are Mixed on These Healthcare Stocks: Surgery Partners (SGRY) and Keros Therapeutics (KROS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Surgery Partners (SGRY – Research Report) and Keros Therapeutics (KROS – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Surgery Partners (SGRY)
In a report released today, Ryan Langston from TD Cowen maintained a Buy rating on Surgery Partners, with a price target of $20.00. The company’s shares closed last Wednesday at $14.08.
According to TipRanks.com, Langston is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Surgery Partners has an analyst consensus of Strong Buy, with a price target consensus of $21.07, representing a 52.2% upside. In a report issued on March 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $33.00 price target.
See today’s best-performing stocks on TipRanks >>
Keros Therapeutics (KROS)
In a report released today, Matt Phipps from William Blair maintained a Hold rating on Keros Therapeutics. The company’s shares closed last Wednesday at $13.77, close to its 52-week low of $9.78.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Keros Therapeutics with a $21.50 average price target.
